Sangamo Therapeutics Inc was incorporated in the State of Delaware on June 22, 1995. The Company is engaged in translating ground-breaking science into genomic therapies that transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Its proprietary zinc finger DNA-binding proteins (ZFP) technology enables efficient and highly specific genome editing and gene regulation, and are developing genome editing and gene therapies for the treatment of genetically tractable diseases.